Infliximab
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Infliximab: From TNF-α–Driven Autoimmune Disease to Rheumatoid Vasculitis
One-Sentence Summary
Infliximab is a chimeric anti-TNF-α monoclonal antibody established for treating chronic TNF-α–driven inflammatory diseases. This evidence pack evaluated 10 TxGNN-predicted indications for infliximab; the most clinically meaningful novel candidate is Rheumatoid Vasculitis, supported by 4 indirectly related clinical trials and 20 publications, though the literature evidence is genuinely mixed — some reports show therapeutic benefit while others describe infliximab paradoxically inducing vasculitis.
(Note: Several other predicted indications in this pack — inflammatory spondylopathy, polyarticular juvenile rheumatoid arthritis, perianal Crohn’s disease/”anus disease”, and Crohn’s disease of the esophagus — are largely re-identifications of infliximab’s already-established indications rather than novel repurposing candidates; these are summarised in the appendix table below.)
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in this evidence pack (no ARTG licence data available). Infliximab is generally established for chronic TNF-α–driven inflammatory disease (e.g. rheumatoid arthritis, Crohn’s disease) |
| Predicted New Indication | Rheumatoid Vasculitis |
| TxGNN Prediction Score | 85.32% |
| Evidence Level | L3 |
| Australia Market Status | Not marketed (未上市) |
| Number of ARTG Entries | 0 |
| Recommended Decision | Research Question |
Why is This Prediction Reasonable?
Detailed mechanism-of-action data is not available in this evidence pack (Data Gap DG002). Based on general pharmacological knowledge, infliximab is a chimeric IgG1 monoclonal antibody that binds and neutralises both soluble and membrane-bound TNF-α, and is an established therapy for chronic inflammatory autoimmune conditions.
Rheumatoid vasculitis (RV) is one of the most severe extra-articular manifestations of rheumatoid arthritis, driven by TNF-α–mediated endothelial injury and immune-complex deposition. Since infliximab already suppresses the same TNF-α pathway that drives joint inflammation in RA, it is mechanistically plausible that it could also suppress the vascular inflammation seen in RV — several case reports and a systematic review describe good clinical responses.
However, the evidence is not one-directional: multiple case reports in this same evidence pack describe infliximab paradoxically inducing cutaneous, renal and CNS vasculitis in patients being treated for RA. This “paradoxical” phenomenon is a recognised but poorly understood effect of TNF inhibitors, and it means the mechanistic case for infliximab as an RV treatment is genuinely contested rather than one-sided — this is why the recommendation is “Research Question” rather than a stronger designation.
Clinical Trial Evidence
No trials specifically designed to test infliximab for rheumatoid vasculitis were identified. The following are indirectly related trials (RA/biologics context) surfaced by the search:
| Trial Number | Phase | Status | Enrolment | Key Findings |
|---|---|---|---|---|
| NCT07138898 | Phase 2 | Not yet recruiting | 80 | Perioperative immunosuppressant (incl. anti-TNF) management in rheumatology patients undergoing shoulder arthroplasty — not an RV efficacy trial |
| NCT05696106 | N/A | Unknown | 750,000 | Large registry study of incident immune-mediated inflammatory disease risk in patients on biologics, including vasculitis-related risk |
| NCT02590562 | N/A | Completed | 808 | Cross-sectional study of biologic DMARD treatment patterns in RA patients in China — not RV-specific |
| NCT01579006 | N/A | Completed | 184 | Non-interventional study of tocilizumab (not infliximab) in RA — included for background only |
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 33058033 | 2021 | Systematic Review | Clinical Rheumatology | Systematic review of biologic drugs (including infliximab) in rheumatoid vasculitis; supports use as part of the therapeutic armamentarium |
| 16078342 | 2005 | Case Series | The Journal of Rheumatology | Patient with RV showed good response to infliximab; suggests anti-TNF as an option for refractory systemic RV |
| 15801041 | 2005 | Case Report | The Journal of Rheumatology | Successful treatment of RV-associated foot-drop with infliximab |
| 28123776 | 2017 | Cohort | RMD Open | BSRBR-RA registry: compares risk of lupus-like and vasculitis-like events between TNF inhibitors and non-biologic DMARDs |
| 40385904 | 2025 | Case Report | Cureus | Infliximab-induced leukocytoclastic vasculitis in a well-controlled RA patient — paradoxical safety signal |
| 35650123 | 2023 | Case Report | Internal Medicine (Tokyo) | Endothelial damage-dominant IgA vasculitis nephritis after 11 years of infliximab use for RA — paradoxical safety signal |
| 17712519 | 2008 | Case Report | Clinical Rheumatology | C-ANCA-positive systemic vasculitis in an RA patient treated with infliximab — paradoxical safety signal |
| 34068884 | 2021 | Review | Journal of Clinical Medicine | Review of RA-associated episcleritis/scleritis (an ocular vasculitic manifestation) and its treatment |
| 16966021 | 2006 | Review | Clinics in Dermatology | General review of cutaneous vasculitis diagnosis and classification (background context) |
| 19951375 | 2010 | — | Allergy | Anti-infliximab IgE and non-IgE antibodies linked to infusion-related anaphylactic reactions — relevant safety mechanism |
Australia Market Information
No ARTG entries are recorded for infliximab in this evidence pack (market status: not marketed, 0 licences).
Safety Considerations
Please refer to the TGA-approved Product Information (PI) for formal safety information — key warnings, contraindications and drug-interaction data are not available in this evidence pack (Data Gap DG001, classified as Blocking — this must be resolved before any S1 safety assessment).
Evidence-derived safety signal (from literature, not official PI): Several case reports in this evidence pack (PMID 40385904, 35650123, 17712519, 15853915, 11792895, 16207269) describe infliximab paradoxically inducing cutaneous, renal, or CNS vasculitis in patients being treated for RA. Given the predicted new indication is treatment of vasculitis itself, this paradoxical signal is a critical consideration and a central reason the evidence is rated “Research Question” rather than a stronger recommendation.
Conclusion and Next Steps
Decision: Research Question
Rationale: Evidence for infliximab in rheumatoid vasculitis consists of a systematic review, small case series, and a cohort risk study — no dedicated RCTs exist, and the evidence direction is contested by paradoxical vasculitis-induction case reports. This does not yet support a Go/Proceed decision but is a legitimate area for structured research.
To proceed, the following is needed:
- TGA-approved Product Information / TFDA label data (key warnings, contraindications, DDI) — currently a Blocking data gap
- Confirmed mechanism-of-action documentation (DG002)
- A dedicated observational or prospective study distinguishing therapeutic response from paradoxical induction risk in RV patients specifically
- Clarification of Australian registration/import pathway, since infliximab currently has zero ARTG entries in this dataset
Appendix: Other TxGNN-Predicted Indications (for context)
| Disease | TxGNN Score | Evidence Level | Recommendation | Note | |—|—|—|—|—| | Colobomatous microphthalmia-rhizomelic dysplasia syndrome | 90.22% | L5 | Hold | No mechanistic or clinical link; likely graph-link noise | | Brachydactyly-syndactyly syndrome | 89.88% | L5 | Hold | Non-inflammatory congenital disorder; no relevant link | | Hypermobility of coccyx | 82.49% | L5 | Hold | Structural/mechanical condition; no relevant link | | Kummell disease | 81.15% | L5 | Hold | Osteoporotic vertebral collapse; no relevant link | | Inflammatory spondylopathy | 80.92% | L1 | Proceed with Guardrails | Already an approved anti-TNF indication (ankylosing spondylitis) — not a novel finding | | Polyarticular juvenile rheumatoid arthritis | 80.14% | L1 | Proceed with Guardrails | Already an approved paediatric anti-TNF indication — not a novel finding | | Bronchitis | 77.87% | L4 | Hold | Conflicting case reports (both benefit and infliximab-induced pulmonary inflammation); no dedicated trials | | Anus disease (≈ perianal Crohn’s) | 81.21% | L2 | Proceed with Guardrails | Represents fistulising Crohn’s disease, an existing approved indication | | Crohn disease of the esophagus | 77.58% | L3 | Proceed with Guardrails | Rare-site extension of an already-approved indication (Crohn’s disease) |
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.